1 / 17

Maternal and fetal safety of nevirapine-containing HAART regimens during pregnancy

Maternal and fetal safety of nevirapine-containing HAART regimens during pregnancy. Oriol Coll 1 , Montse Loncà 1 , Imma Ocaña 2 , Marta López 1 , Marjorie Diaz 2 , Mila Montero 3 , Sandra Hernández 1 , Francesc Figueras 1 , Anna Suy 2 , Ana Guelar 3.

nau
Download Presentation

Maternal and fetal safety of nevirapine-containing HAART regimens during pregnancy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Maternal and fetal safety of nevirapine-containing HAART regimens during pregnancy Oriol Coll1, Montse Loncà1, Imma Ocaña2, Marta López1, Marjorie Diaz2, Mila Montero3, Sandra Hernández1, Francesc Figueras1, Anna Suy2, Ana Guelar3 • 1Hospital Clínic University of Barcelona. • 2Hospital Vall d' Hebron Autonomous University of Barcelona • 3Hospital del Mar Autonomous University of Barcelona

  2. Hitti J. J Acquir Immune Defic Syndr 2004;36:772–776 PACTG 1022. RCT (All ZDV + LMV + NFV vs NVP) 10-30 week’s gestation Toxicity* p n % Nelfinavir 1 / 21 5 Nevirapine 5 / 17 29 0.07 *Treatment-limiting hepatic or cutaneous toxicity All 5 events: CD4 > 250 cells/μL (P = 0.04). Study suspended

  3. Joy S. Obstet Gynecol 2005;106:1032–3 Retrospective study (7/2001 – 4/2005). 23 pregnancies Adverse events: 3 / 23 13% Initiation of nevirapine 3rd trimester 3 / 5 60% Earlier 0/18 0% P < .006 All > 27 weeks p., first 6 weeks of therapy and CD4+ cell count > 250 cells/µL

  4. Methods: Retrospective multicenter study (3 centers) University of Barcelona - Hospital Clínic. Autonomous University of Barcelona- Hospital Vall d' Hebron and Hospital del Mar Inclusion criteria: - All women who received HAART during pregnancy (≥ 2 weeks) - Delivered ≥ 22 weeks of gestation - Study period: July 1st 1997 and December 31st 2005. - Toxic events defined as (standard criteria) Objective To establish maternal and fetal safety of nevirapine-containing HAART regimens during pregnancy

  5. 1- Maternal toxicity: Skin rash Hepatotoxicity (NIAID toxicity guidelines) 2- Adverse perinatal outcome: Preterm delivery Small for gestational age Preeclampsia Intrauterine fetal demise - Statistical analysis - Sponsored by Boehringer Ingelheim

  6. Initiation of NVP use n % Prior to conception 79 41.4 After conception 112 58,7 Results Patients: 311 women(HAART during pregnancy) Regimens n % NVP-containing 191 61.4 Non NVP containing 120 38.6

  7. NVP containing regimens (n=191) Non-NVP containing regimens (n=120) p Age (Mean (range)) 31.3 (17-42) 31.3 (16-40) 0.97+ Caucasian ethnicity; n(%) 150/191 (78.5) 110/120 (91.7) 0.002* Primiparity; n(%) 84/191 (44) 55/120 (45.8) 0.75* Toxics in pregnancy; n(%) Smoking Other drugs 96/191 (50.3) 13/191 (6.8) 82/120 (68.3) 23/120 (19.2) 0.002* 0.001* Co-infection; n(%) HCV HbsAg 70/190 (36.8) 8/189 (4.2) 62/120 (51.7) 3/120 (2.5) 0.01* 0.42* Socio-demographic characteristics + T-test; * Chi-squared test.

  8. NVP containing regimens (n=191) Non-NVP containing regimens (n=120) p Diagnosis pre-pregnancy; n(%) 155/191(81.2) 108/120(90) 0.036+ Months from HIV diagnosis to delivery; (median(range)) 72(0-206) 84(1-228) 0.05# Months on HAART from diagnosis to conception; (median(range)) 11.14(0-98) 13 (0-111) 0.866# Weeks on HAART from conception to delivery; (median(range)) 33.7(0.83-40) 33.9(4-39.7) 0.909# Basal CD4 (<250 cell/mm3) ; n(%) (basal) 28(14.7) 25(20.8) 0.076+ ARVT at conception; n(%) Naive No current ARVT Non HAART regimen HAART regimen 78 (40.8) 1 (0.5) 1 (0.5) 110 (57.6) 43 (35.8) 3 (2.5) 3 (2.5) 70 (58.3) 0.378+ 0.162* 0.163* 0.897+ HIV-Related variables + Chi-squared test; # Mann-Whitney test; * Exact Fisher Test

  9. TotalNVP containingNVP containing p n=311 regimens n= 191 regimens n= 120 n (%) n (%) n (%) Hepatotoxicity 9 (2,9) 9 (4.7) 0 (0) 0.014* Skin rash 10 (3,2) 10 (5.2) 0 (0) 0.008* Toxic events 19 Patients 17 (5,5) 17 (8.9) 0 <0.001+ + Chi-squared test; * Exact Fisher Test Toxic events among patients with HAART during pregnancy

  10. TotalNVP containingNon-NVP containing p n=311 regimens n= 191 regimens n= 120 n (%) n (%) n (%) Hepatotoxicity 9 (2,9) 9 (4.7) 0 (0) 0.014* Skin rash 10 (3,2) 10 (5.2) 0 (0) 0.008* Toxic events 19 Patients 17 (5,5) 17 (8.9) 0 <0.001+ + Chi-squared test; * Exact Fisher Test Toxic events among patients with HAART during pregnancy

  11. No cases of fulminant hepatitis or maternal death occurred Acute toxic hepatitis and/or severe rash: 6 / 191 (3.1%) Toxic events among patients with HAART during pregnancy Hepatotoxic events n Grade 1-2 5 Acute toxic hepatitis 4 Rash n Mild / Moderate 6 Severe 4 ( 1: Lyell Syndrome and 2 + hepatic toxicity)

  12. Toxicity and Cd4+ cell counts • n % p • >250 cells/µL   13 / 162 8 • <250 cells/µL 4 / 28 14,3 0.65  Toxic events among patients with HAART during pregnancy • Interval betweeninitiation of NVP and toxic event (median and range): 4 weeks (1-12weeks) • Toxicity and initiation of NVP • n % • Prior to conception 1 / 79 1,3 • During pregnancy 16 / 112 14,3

  13. Initiation of Nevirapine Total n Toxicity n (%) 1-2ST trimester(0-27,6weeks) 88 14 (15.9) 3RD trimester(28-term) 24 2 (8.3) Total 112 16 (14.3) Toxic events according to trimester of initiation of NVP

  14. NVP containing regimens (n=191) Non-NVPcontaining regimens (n=120) p Premature delivery Small for gestational age Pre-eclampsia Intrauterine fetal demise 38 (19.9) 26 (13.6) 10 (5.2) 6 (3.1) 30 (25) 19 (15.8) 7 (5.8) 2 (1.7) 0.289+ 0.588+ 0.821+ 0.715* Adverse outcome 59 (30.9) 49 (40.8) 0.073+ HIV-1 vertical transmission 2/185 (1.7) 2/118 (1.1) 0.648* Adverse perinatal outcome in NVP and non-NVP containing regimens during pregnancy + Chi-squared test; * Exact Fisher Test.

  15. NVP containing regimen Yes (n=191) No (n=120) OR (95% CI) Adverse event Maternal toxicity (n=17) Adverse perinatal outcome (n=108) 17 (8.9) 59 (30.9) 0 (0) 49 (40.8) - 0.65 (0.4-1.04) Summary of adverse event in NVP and NVP containing regimens during pregnancy Adjusted for parity, ethnicity, smoking and drug consumption OR(95%CI) for adverse outcome: 0.78 (0.47-1.29)

  16. Conclusions • All toxic events occurred in women on NVP-containing regimens, but the incidence was similar than the one described in non-pregnant women • Almost all cases occurred in newly treated patients • The occurrence of toxicity was not associated to immunological status or trimester of initiation of therapy • A non-significant lower incidence of adverse perinatal outcome among these women was observed • The use of nevirapine-containing regimens during pregnancy may be justified in selected cases • ocoll@clinic.ub.es

More Related